
Opinion|Videos|October 7, 2024
Treatment Expectations and Patient Conversations in Atopic Dermatitis
Key Takeaways
- Setting treatment expectations is vital for building trust and aligning patient-physician goals in oncology.
- Continuous dialogue about treatment targets keeps patients informed and engaged in their care.
Medical experts discuss the importance of setting treatment expectations and maintaining dialogue with patients about targets and explain how to decide on a new treatment when switching.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How important is it to set treatment expectations? Do you have an ongoing dialogue with patients about achieving targets?
- How do you determine which treatment to switch to?
Advertisement
Related to this article

For Eczema Awareness Month, Keira Barr, MD, explains the stress-itch cycle in atopic dermatitis and questions to uncover its hidden burden in clinic.

Stephan Weidinger, MD, PhD, discusses 5-year ADlong data showing durable skin clearance and itch control with lebrikizumab in atopic dermatitis.

The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.

Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.

Participants described how payer requirements and documentation of steroid exposure shape biologic access.

In TRANSCEND-CKD, retatrutide reduced UACR by 49.2% vs placebo and lowered intraglomerular pressure and kidney fat without changing measured GFR at 24 weeks.

Ravulizumab cut proteinuria 43.4% vs placebo at week 34 in I CAN, making it the first C5 inhibitor approved for IgA nephropathy under accelerated approval.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
3
Kidney Compass: ORIGIN 3 Final eGFR Data for Atacicept in IgA Nephropathy
4
FDA Approves Berotralstat Oral Pellets for Adults, Adolescents With HAE
5

